The stock of National Bank of Greece (ADR) (NYSE:NBG) recently received an upgrade from equity analysts at Piraeus Securities given the improvement in the bank’s risk/return profile. The analysts upgraded the stock to an “outperform” rating from their previously assigned “neutral” rating. Analyst at Piraeus Securities, Natasha Roumantzi recent upgrade follows JP Morgan’s upgrade on the stock where analysts confirmed an “overweight” rating for National Bank of Greece. Previously, analysts at JP Morgan had assigned a “neutral” rating on the stock. National Bank of Greece (ADR) (NYSE:NBG) net profit margin is 11.20% and weekly performance is 6.27%. On last trading day company shares ended up $3.22. Analysts mean target price for the company is $4.65. National Bank of Greece (ADR) (NYSE:NBG) distance from 50-day simple moving average (SMA50) is -28.66%.
Morgan Stanley (NYSE:MS) and JPMorgan Chase & Co have sold off large parts of their physical trading businesses, while Barclays PLC and Deutsche Bank AG are quitting the commodity markets altogether. Morgan Stanley (NYSE:MS) shares advanced 0.33% in last trading session and ended the day on $30.49. Gross Margin is 84.00% and its return on assets is 0.50%. Morgan Stanley (NYSE:MS) quarterly performance is 0.93%.
MacroGenics, Inc. (NASDAQ:MGNX) a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, and Takeda Pharmaceutical Company Limited jointly announced that they have entered into an option agreement for the development and commercialization of MGD010. This product candidate incorporates MacroGenics’ proprietary platform for Dual-Affinity Re-Targeting (DART(R)) to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. MGD010 is currently in pre-clinical development for the treatment of autoimmune diseases. MacroGenics Inc (NASDAQ:MGNX) shares moved up 0.16% in last trading session and was closed at $18.53, while trading in range of $18.03- $18.96. MacroGenics Inc (NASDAQ:MGNX) year to date (YTD) performance is -32.45%.
Gilead Sciences Inc (NASDAQ:GILD) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report released on Friday. The firm currently has a $99.00 price objective on the stock. Zacks‘s price objective indicates a potential upside of 22.31% from the company’s current price. Gilead Sciences, Inc. (NASDAQ:GILD) ended the last trading day at $80.94. Company weekly volatility is calculated as 2.11% and price to cash ratio as 19.21. Gilead Sciences, Inc. (NASDAQ:GILD) showed a positive weekly performance of 0.17%.
Suntech Power Holdings Co., Ltd. (ADR) (OTCMKTS:STPFQ) predicts that the cost of building large scale solar PV plants could match the cost of coal-fired generation in China by 2016, a development that will “completely transform” the energy market in the world’s second biggest economy. Suntech Power Holdings Co., Ltd. (ADR) (OTCMKTS:STPFQ) On last trading day company shares ended up $0.303 .